特写独家！萌兽联盟集结！合家欢动画《大旅行》角色海报萌趣来袭

萌兽联盟集结！合家欢动画《大旅行》角色海报萌趣来袭

今日，备受期待的合家欢动画电影《大旅行》发布了萌兽联盟版角色海报。熊猫宝宝和国宝护卫队成员一一亮相，萌态各异，尽显个性，为即将于4月8日全国上映的影片增添了浓浓的欢乐气息。

角色海报以清新明快的画风展现了影片中的主要角色。 熊猫宝宝圆圆的大眼睛和软萌的外表让人心生喜爱，而国宝护卫队的成员们也各具特色：勇猛强壮的棕熊米米、机灵敏捷的兔子奥斯卡、博学多才的鹈鹕尼古拉、胆小怕事的灰狼瓦西里以及浪漫温柔的老虎谢尔盖，他们性格迥异，却为了同一个目标走到了一起，组成了一支充满笑料和温情的萌兽联盟。

海报中，熊猫宝宝正抱着竹子开心地啃食，米米和奥斯卡则一左一右地守护在它身旁，眼神充满关爱。 尼古拉站在一边讲述着故事，瓦西里躲在米米身后瑟瑟发抖，谢尔盖则深情地凝望着远方，似乎在思考着什么。这幅其乐融融的画面展现了国宝护卫队成员之间深厚的友谊，也预示着他们将在冒险旅途中经历的种种趣事。

《大旅行》讲述了熊猫宝宝被误送给棕熊后，被好心的米米和淘气兔奥斯卡带领的国宝护卫队护送回家的欢乐冒险故事。 影片在轻松幽默的氛围中传递了友爱、勇气和善良的正能量，非常适合亲子共同观看。

萌兽联盟已经集结完毕，即将踏上欢乐的旅程。 让我们一起期待《大旅行》的上映，感受动画电影带来的无限欢乐吧！

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.